After $62M funding round, CRO Fountain Medical nabs new leader

China-based Fountain Medical got off a hefty series D round back in the fall. (Pixabay)

Contract research organization veteran Ling Zhen, J.D., MBA, has been scooped up as China’s Fountain Medical’s new chief and co-chairman.

Zhen has spent a quarter of a century in life sciences, is a former alum of IQVIA (formerly Quintiles) in China and served stints at Eli Lilly, GlaxoSmithKline and Ernst &Young in the U.S.

He comes to Fountain Medical from being a partner at Draper Dragon Venture Group; as CEO, he will “speed up its global expansion and strategic build-up,” according to the company, which, since its founding in 2017, has been working on services include clinical operations, biostatistics, regulatory affairs, pharmacovigilance, medical affairs and clinical monitoring.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Dr. Dan Zhang, co-chairman and co-founder of the CRO, said: “His hands-on experience and strategic insight related to the CRO sector makes him the ideal leader to transform Fountain Medical into a China-centered, global full-service leading CRO.”

The company got off a $62 million series D round back in October, with cash coming from the likes of DFJ Dragon Fund and Lilly Asia Ventures.

“I feel very privileged to join Fountain Medical during this exciting time, where drug development and clinical research are undergoing transformational changes across China and rest of the world," added Zhen.

“I look forward to working closely with Fountain Medical's management team and shareholders, and developing a high-caliber team that delivers high-quality services, to help our customers accelerate the development of truly innovative therapies around the world.”

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

Baxter has received clearance from the FDA for the latest version of its automated peritoneal dialysis system designed for home use.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.